

Analysis of drug interactions in patients with heart disease: An experience report

Análise das interações medicamentosas em doentes com doença cardíaca: Um relato de experiência

DOI: 10.56238/isevmjv2n2-006 Receiving the originals: 01/03/2023 Acepptance for publication: 20/03/2023

Pedro de Almeida Rischard Poletto

Medical course academic. E-mail: polettomed@gmail.com

Rafaela Bernardo Alaite

Medical course academic. E-mail: rafaalaite@uni9.edu.br

Laura Alves Estevo

Medical course academic. E-mail: lauraestevo@uni9.edu.br

Luiz Minuzo Professor of the medical course. E-mail:dr.minuzzo@uol.com.br

Luciana Vismari

Professor of the medical course. E-mail: luvismari@gmail.com

ABSTRACT

Cardiopathic patients routinely use multiple medications. This polypharmacy, although an important strategy for the control of comorbidities, can lead to numerous drug interactions, in addition to results of altered magnitude and specificity¹. These interactions can be beneficial and expected, increasing treatment effectiveness, but they can also be undesirable, causing the opposite effect to the desired one².

Keywords: Interaction, Omeprazole, Clopidogrel.

1 INTRODUCTION

Cardiopathic patients routinely use multiple medications. This polypharmacy, although an important strategy for the control of comorbidities, can lead to numerous drug interactions, in addition to results of altered magnitude and specificity¹. These interactions can be beneficial and expected, increasing treatment effectiveness, but they can also be undesirable, causing the opposite effect to the desired one².



2 OBJECTIVE

To report the experience of caring for a cardiac patient admitted to a public hospital with a complaint of anginal pain, focusing on discussing the possible impact of drug interactions on the ischemic presentation.

3 CASE REPORT

Male patient, 58 years old, with a history of three acute myocardial infarctions between 2009 and 2018, diabetic with glycated hemoglobin of 11.2%, (reference value (RV) <5.7%), dyslipidemic with LDL of 188 mg/dL (RV < 50 mg/dL), hypertensive, former smoker 62 years/pack, former severe alcoholic, reported anginal pain of intensity 10/10 on effort. Medications in use: omeprazole 20 mg, ASA 100 mg, carvedilol 25 mg, clopidogrel 75 mg, enalapril 5 mg, spironolactone 25 mg, metformin 850 mg, gliclazide 60 mg, atorvastatin 40 mg, dipyrone 500 mg. The Drugs.com database analysis of the drugs detected fourteen interactions: three (22%) mild, nine (64%) moderate, and two (14%) severe. Gliclazide is not included in the database used. Among the serious interactions is the association between spironolactone and enalapril, which can lead to hyperkalemia (not observed in the patient's tests). The co-administration of omeprazole and clopidogrel is associated with a decrease in the effect of the platelet antiaggregant, although no test to check platelet activity has been performed.

4 FINAL CONSIDERATIONS

The analysis suggests that the omeprazole-clopidogrel interaction may have culminated in decreased effectiveness of antiaggregant therapy. This fact was added to uncontrolled diabetes and dyslipidemia, increasing the risk of a new ischemic event. Therefore, a careful evaluation of the prescriptions is necessary in order to detect possible interactions, avoiding the risks of these interactions to be added to those of other comorbidities, ensuring the effectiveness of the instituted therapy.



REFERENCES

Jain S, Jain P, Sharma K, Saraswat, P. A Prospective Analysis of Drug Interactions in Patients of Intensive Cardiac Care Unit. *J Clin Diagn Res.* 2017 Mar 1;11(3): FC01–FC04.

Bundhun, PK, Teeluck, AT, Bhurtu, A, Huang,W-Q. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 – 2016). *BMC Cardiovasc Disord, 2017 Jan 5;* 17,

Nag,K. Arvind, Umesh, M, Churi, S. Assessment of drug-drug interactions in hospitalised patients in India. Asian Journal of Pharmaceutical and Clinical Research, 2011 September; 4, 62-65.